Applied pharmacogenomics in cardiovascular medicine

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 81-94

  Weeke, Peter ^a,b   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Clopidogrel; Genetics; Personalized medicine; Polymorphisms; Statin; Warfarin

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CARDIOVASCULAR AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1; WARFARIN;

ALLELE; AMINO ACID SEQUENCE; CAUCASIAN; DRUG ACTIVATION; DRUG METABOLISM; DRUG RESPONSE; GAIN OF FUNCTION MUTATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INDEL MUTATION; LONG QT SYNDROME; META ANALYSIS (TOPIC); MYALGIA; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMOTER REGION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; THROMBOCYTE AGGREGATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ANTITHROMBINS; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84901481682     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-101712-122545     Document Type: Review

References (99)

1. Gu Q, Dillon CF, Burt VL. 2010. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief, pp. 1-8
2. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-5 (Pubitemid 28193431)
3. Sykiotis GP, Kalliolias GD, Papavassiliou AG. 2005. Pharmacogenetic principles in the Hippocratic writings. J. Clin. Pharmacol. 45:1218-20 (Pubitemid 41513043)
4. Kim MJ, Huang SM, Meyer UA, et al. 2009. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol. 49:138-46
5. Aithal GP, Day CP, Kesteven PJ, et al. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-19 (Pubitemid 29103806)
6. Rettie AE, Haining RL, Bajpai M, et al. 1999. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35:253-55 (Pubitemid 29298118)
7. Lindh JD, Holm L, Andersson ML, et al. 2009. Influence of CYP2C9 genotype on warfarin dose requirements-a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65:365-75
8. Cooper GM, Johnson JA, Langaee TY, et al. 2008. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-27
9. Ross KA, Bigham AW, Edwards M, et al. 2010. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 55:582-89
10. Wadelius M, Chen LY, Lindh JD, et al. 2009. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-92
11. Wang D, Chen H, Momary KM, et al. 2008. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112:1013-21
12. Rost S, Fregin A, Ivaskevicius V, et al. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-41 (Pubitemid 38209110)
13. Rieder MJ, Reiner AP, Gage BF, et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352:2285-93 (Pubitemid 40740552)
14. Scott SA, Edelmann L, Kornreich R, et al. 2008. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82:495-500
15. Allabi AC, Gala JL, Horsmans Y. 2005. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15:779-86 (Pubitemid 41531727)
16. Takeuchi F, McGinnis R, Bourgeois S, et al. 2009. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5:e1000433
17. Caldwell MD, Awad T, Johnson JA, et al. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-12
18. Danese E, Montagnana M, Johnson JA, et al. 2012. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin. Pharmacol. Ther. 92:746-56
19. Anderson JL, Horne BD, Stevens SM, et al. 2012. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125:1997-2005
20. Caraco Y, Blotnick S, Muszkat M. 2008. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther. 83:460-70 (Pubitemid 351272635)
21. Epstein RS, Moyer TP, Aubert RE, et al. 2010. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55:2804-12
22. Finkelman BS, Gage BF, Johnson JA, et al. 2011. Genetic warfarin dosing: tables versus algorithms. J. Am. Coll. Cardiol. 57:612-18
23. Gage BF, Eby C, Johnson JA, et al. 2008. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84:326-31
24. Johnson JA, Gong L, Whirl-Carrillo M, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90:625-29
25. French B, Joo J, Geller NL, et al. 2010. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11:108
26. Pare G, Eriksson N, Lehr T, et al. 2013. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127:1404-12
27. Kazui M, Nishiya Y, Ishizuka T, et al. 2010. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38:92-99
28. Hulot JS, Bura A, Villard E, et al. 2006. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-47 (Pubitemid 44497506)
29. Goldstein JA. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52:349-55 (Pubitemid 32939439)
30. Kim KA, Park PW, Hong SJ, et al. 2008. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84:236-42
31. Mega JL, Close SL, Wiviott SD, et al. 2009. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360:354-62
32. Umemura K, Furuta T, Kondo K. 2008. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb. Haemost. 6:1439-41 (Pubitemid 352016331)
33. Fontana P, Hulot JS, De Moerloose P, et al. 2007. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost. 5:2153-55 (Pubitemid 47450038)
34. Brandt JT, Close SL, Iturria SJ, et al. 2007. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5:2429-36 (Pubitemid 350154353)
35. Frere C, Cuisset T, Morange PE, et al. 2008. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am. J. Cardiol. 101:1088-93
36. Shuldiner AR, O'Connell JR, Bliden KP, et al. 2009. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-57
37. Collet JP, Hulot JS, Pena A, et al. 2009. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-17
38. Simon T, Verstuyft C, Mary-Krause M, et al. 2009. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360:363-75
39. Mega JL, Simon T, Collet JP, et al. 2010. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-30
40. Trenk D, Hochholzer W, Fromm MF, et al. 2008. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51:1925- 34 (Pubitemid 351636443)
41. Delaney JT, Ramirez AH, Bowton E, et al. 2012. Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin. Pharmacol. Ther. 91:257-63
42. Wallentin L, Becker RC, Budaj A, et al. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361:1045-57
43. Pare G, Mehta SR, Yusuf S, et al. 2010. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363:1704-14
44. Holmes MV, Perel P, Shah T, et al. 2011. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306:2704-14
45. Johnson JA, Roden DM, Lesko LJ, et al. 2012. Clopidogrel: a case for indication-specific pharmacogenetics. Clin. Pharmacol. Ther. 91:774-76
46. Sibbing D, Koch W, Gebhard D, et al. 2010. Cytochrome 2C1917 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121:512-18
47. Wallentin L, James S, Storey RF, et al. 2010. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376:1320-28
48. Scott SA, Sangkuhl K, Gardner EE, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90:328-32
49. Holmes DR Jr, Dehmer GJ, Kaul S, et al. 2010. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 122:537-57
50. Davidson MH, Maki KC, Pearson TA, et al. 2005. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96:556-63 (Pubitemid 41132774)
51. Law M, Rudnicka AR. 2006. Statin safety: a systematic review. Am. J. Cardiol. 97:52C-60C
52. Mangravite LM, Thorn CF, Krauss RM. 2006. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6:360-74 (Pubitemid 44811531)
53. Chasman DI, Posada D, Subrahmanyan L, et al. 2004. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291:2821-27 (Pubitemid 38747801)
54. Krauss RM, Mangravite LM, Smith JD, et al. 2008. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme A reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117:1537-44 (Pubitemid 351440642)
55. MedinaMW, Gao F, Ruan W, et al. 2008. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118:355-62
56. Mangravite LM, Medina MW, Cui J, et al. 2010. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler. Thromb. Vasc. Biol. 30:1485-92
57. Iakoubova OA, Sabatine MS, Rowland CM, et al. 2008. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51:449-55
58. Iakoubova OA, Tong CH, Rowland CM, et al. 2008. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE andWOSCOPS trials. J. Am. Coll. Cardiol. 51:435-43
59. AssimesTL, HolmH, Kathiresan S, et al. 2010. Lack of association between theTrp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J. Am. Coll. Cardiol. 56:1552-63
60. Hopewell JC, Parish S, Clarke R, et al. 2011. No impact of KIF6 genotype on vascular risk and statin response among 18, 348 randomized patients in the heart protection study. J. Am. Coll. Cardiol. 57:2000-7
61. Cohen JC, Hobbs HH. 2013. Simple genetics for a complex disease. Science 340:689-90
62. Thompson PD, Clarkson P, Karas RH. 2003. Statin-associated myopathy. JAMA 289:1681-90 (Pubitemid 37430274)
63. Wilke RA, Moore JH, Burmester JK. 2005. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 15:415-21 (Pubitemid 40835083)
64. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16:873-79 (Pubitemid 44772805)
65. Link E, Parish S, Armitage J, et al. 2008. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359:789-99
66. Voora D, Shah SH, Spasojevic I, et al. 2009. The SLCO1B15 genetic variant is associated with statininduced side effects. J. Am. Coll. Cardiol. 54:1609-16
67. Wilke RA, Ramsey LB, Johnson SG, et al. 2012. The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92:112- 17
68. Puccetti L, Ciani F, Auteri A. 2010. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211:28-29
69. Muthumala A, Drenos F, Elliott PM, et al. 2008. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur. J. Heart Fail. 10:3-13
70. Rathz DA, Brown KM, Kramer LA, et al. 2002. Amino acid 49 polymorphisms of the human beta1- adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 39:155-60 (Pubitemid 34093534)
71. Johnson JA, Liggett SB. 2011. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin. Pharmacol. Ther. 89:366-78
72. Mason DA, Moore JD, Green SA, et al. 1999. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. 274:12670-74
73. Chen L, Meyers D, Javorsky G, et al. 2007. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet. Genomics 17:941-49 (Pubitemid 350293794)
74. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. 2006. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl. Acad. Sci. USA 103:11288-93
75. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. 2010. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ. Heart Fail. 3:21-28
76. Karlsson J, Lind L, Hallberg P, et al. 2004. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin. Cardiol. 27:347-50 (Pubitemid 38703089)
77. Liu J, Liu ZQ, Yu BN, et al. 2006. Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 80:23-32 (Pubitemid 43946840)
78. Green SA, Turki J, Innis M, et al. 1994. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33:9414-19 (Pubitemid 24272896)
79. de Groote P, Helbecque N, Lamblin N, et al. 2005. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics 15:137-42 (Pubitemid 40569899)
80. Small KM, Wagoner LE, Levin AM, et al. 2002. Synergistic polymorphisms of beta1- and alpha2Cadrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347:1135-42
81. Rau T, Heide R, Bergmann K, et al. 2002. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12:465-72 (Pubitemid 34913529)
82. Bijl MJ, Visser LE, van Schaik RH, et al. 2009. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther. 85:45-50
83. Liggett SB, Cresci S, Kelly RJ, et al. 2008. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat. Med. 14:510-17
84. Cresci S, Kelly RJ, Cappola TP, et al. 2009. Clinical and genetic modifiers of long-term survival in heart failure. J. Am. Coll. Cardiol. 54:432-44
85. Brugts JJ, Isaacs A, Boersma E, et al. 2010. Genetic determinants of treatment benefit of the angiotensinconverting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur. Heart J. 31:1854-64
86. Harrap SB, Tzourio C, Cambien F, et al. 2003. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42:297-303 (Pubitemid 37093476)
87. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. 2010. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 20:532-36
88. Johnson JA. 2010. Pharmacogenomics of antihypertensive drugs: past, present and future. Pharmacogenomics 11:487-91
89. Paulussen AD, Gilissen RA, Armstrong M, et al. 2004. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. (Berl.) 82:182-88
90. Kaab S, Crawford DC, Sinner MF, et al. 2012. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ. Cardiovasc. Genet. 5:91- 99
91. Ramirez AH, Shaffer CM, Delaney JT, et al. 2012. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 13:325-29
92. Yang P, Kanki H, Drolet B, et al. 2002. Allelic variants in long-QT disease genes in patients with drugassociated torsades de pointes. Circulation 105:1943-48 (Pubitemid 34437622)
93. Itoh H, Sakaguchi T, Ding WG, et al. 2009. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ. Arrhythm. Electrophysiol. 2:511-23
94. Jamshidi Y, Nolte IM, Dalageorgou C, et al. 2012. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J. Am. Coll. Cardiol. 60:841-50
95. McCarty CA, Chisholm RL, Chute CG, et al. 2011. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4:13
96. Schildcrout JS, Denny JC, Bowton E, et al. 2012. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92:235-42
97. Manolio TA, Chisholm RL, Ozenberger B, et al. 2013. Implementing genomic medicine in the clinic: the future is here. Genet. Med. 15:258-67
98. Pharmacogenomics knowledge resource: http://www.pharmgkb.org
99. A Catalog of Published Genome-Wide Association Studies: http://www.genome.gov/gwasstudies/Pharmacogenomics Research Network (PGRN): http://www.pgrn.org